JP2527107B2
(ja)
*
|
1991-04-16 |
1996-08-21 |
日本新薬株式会社 |
固体分散体の製造方法
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5879705A
(en)
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5688510A
(en)
*
|
1993-11-18 |
1997-11-18 |
Nippon Shinyaku Co. Ltd. |
Process for producing stable medicinal composition, and pharmaceutical preparation
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
FR2729077A1
(fr)
*
|
1995-01-05 |
1996-07-12 |
Oreal |
Composition cosmetique sous forme d'une pate souple et procede de preparation
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
SE9700135D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
DE69837903T2
(de)
*
|
1997-08-11 |
2008-02-14 |
Pfizer Products Inc., Groton |
Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6106862A
(en)
|
1998-08-13 |
2000-08-22 |
Andrx Corporation |
Once daily analgesic tablet
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
ITMI991316A1
(it)
*
|
1999-06-14 |
2000-12-14 |
Cip Ninety Two 92 S A |
Composizioni farmaceutiche orali a rilascio modificato di mesalazina
|
AU764453B2
(en)
|
1999-10-29 |
2003-08-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
SE0003125D0
(sv)
*
|
2000-09-05 |
2000-09-05 |
Astrazeneca Ab |
Modified polymers
|
IL155637A0
(en)
|
2000-10-30 |
2003-11-23 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US7052706B2
(en)
*
|
2001-06-08 |
2006-05-30 |
Nostrum Pharmaceuticals, Inc. |
Control release formulation containing a hydrophobic material as the sustained release agent
|
US7022342B2
(en)
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US6986901B2
(en)
*
|
2002-07-15 |
2006-01-17 |
Warner-Lambert Company Llc |
Gastrointestinal compositions
|
EP1531801A1
(de)
*
|
2002-07-10 |
2005-05-25 |
Warner-Lambert Company LLC |
Kombination eines allosterischen inhibitors oder matrix- metalloproteinase-13 mit einem selektiven inhibitor von cyclooxygenase-2, bei dem es sich nicht um celecoxib oder valdecoxib handelt
|
US20040010035A1
(en)
*
|
2002-07-15 |
2004-01-15 |
Ciociola Arthur A. |
Gastrointestinal compositions
|
KR20040016202A
(ko)
*
|
2002-08-16 |
2004-02-21 |
주식회사 제이알팜 |
쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
|
CA2520813C
(en)
*
|
2003-04-25 |
2009-10-27 |
Mitsubishi Pharma Corporation |
Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
|
US7364755B2
(en)
*
|
2003-07-07 |
2008-04-29 |
Synthon Ip Inc. |
Modified calcium phosphate excipient
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
GB0403098D0
(en)
*
|
2004-02-12 |
2004-03-17 |
Euro Celtique Sa |
Extrusion
|
PL1765292T3
(pl)
|
2004-06-12 |
2018-03-30 |
Collegium Pharmaceutical, Inc. |
Preparaty lecznicze zabezpieczające przed nadużywaniem
|
EP1877040A1
(de)
*
|
2005-04-25 |
2008-01-16 |
Teva Pharmaceuticals USA, Inc. |
Formulierungen mit verlängerter freisetzung
|
AU2006294581B2
(en)
|
2005-09-27 |
2011-11-03 |
Tissuetech, Inc. |
Amniotic membrane preparations and purified compositions and methods of use
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
ES2812250T3
(es)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
RU2443406C2
(ru)
|
2005-12-22 |
2012-02-27 |
Оцука Фармасьютикал Ко., Лтд. |
Способ получения содержащих лекарственное вещество восковых матричных частиц, экструдер для применения в способе и лекарственное средство с замедленным высвобождением, содержащее цилостазол
|
GB0600913D0
(en)
*
|
2006-01-17 |
2006-02-22 |
Syngenta Ltd |
Improvements in or relating to organic compounds
|
US20070185065A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Vikramjit Chhokar |
Combination therapy for coronary artery disease
|
US20070243237A1
(en)
*
|
2006-04-14 |
2007-10-18 |
Mazen Khaled |
Antimicrobial thin film coating and method of forming the same
|
ATE510538T1
(de)
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
HUE031334T2
(hu)
|
2006-09-22 |
2017-07-28 |
Pharmacyclics Llc |
Bruton-tirozinkináz inhibitorok
|
WO2009035818A1
(en)
|
2007-09-10 |
2009-03-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US7981925B2
(en)
|
2008-08-27 |
2011-07-19 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2421901B1
(de)
|
2009-04-24 |
2015-10-28 |
Tissue Tech, Inc. |
Zusammensetzungen mit hc-ha-komplex und verfahren zu ihrer verwendung
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
WO2011090724A2
(en)
*
|
2009-12-29 |
2011-07-28 |
Impax Laboratories, Inc. |
Gastroretentive solid oral dosage forms with lipid-based low-density excipient
|
WO2011130689A1
(en)
|
2010-04-15 |
2011-10-20 |
Tracon Pharmaceuticals, Inc. |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
HUE029570T2
(en)
|
2010-04-27 |
2017-03-28 |
Calcimedica Inc |
Intracellular calcium modifying compounds
|
CN107898791A
(zh)
|
2010-06-03 |
2018-04-13 |
药品循环有限责任公司 |
布鲁顿酪氨酸激酶(btk)抑制剂的应用
|
CA2809830C
(en)
|
2010-08-27 |
2019-09-10 |
Calcimedica, Inc. |
Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
|
WO2012149486A1
(en)
|
2011-04-28 |
2012-11-01 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
US9682044B2
(en)
|
2011-06-10 |
2017-06-20 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
KR101892788B1
(ko)
|
2011-09-13 |
2018-08-28 |
파마싸이클릭스 엘엘씨 |
벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
|
US9364549B2
(en)
*
|
2011-11-30 |
2016-06-14 |
Andreas Voigt |
Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
AU2013207252B2
(en)
|
2012-01-06 |
2016-06-09 |
H.Lundbeck A/S |
Carbamate compounds and pharmaceutical compositions thereof
|
MY194911A
(en)
|
2012-06-04 |
2022-12-22 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
WO2014011813A1
(en)
|
2012-07-11 |
2014-01-16 |
Tissuetech, Inc. |
Compositions containing hc-ha/ptx3 complexes and methods of use thereof
|
US9416141B2
(en)
|
2012-09-28 |
2016-08-16 |
University Of Washington Through Its Center For Commercialization |
Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US9382246B2
(en)
|
2013-12-05 |
2016-07-05 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
EP3253766B1
(de)
|
2015-02-06 |
2019-09-04 |
University of Washington |
Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
US20160243288A1
(en)
|
2015-02-23 |
2016-08-25 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
US20180244631A1
(en)
|
2015-02-27 |
2018-08-30 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
EP3265084B1
(de)
|
2015-03-03 |
2023-11-22 |
Pharmacyclics LLC |
Pharmazeutische formulierungen des bruton-tyrosinkinasehemmers
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
SG10202012002TA
(en)
|
2015-05-11 |
2021-01-28 |
Lundbeck La Jolla Research Center Inc |
Methods of treating inflammation or neuropathic pain
|
JP2018516869A
(ja)
|
2015-05-20 |
2018-06-28 |
ティッシュテック,インク. |
上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
|
US20170209462A1
(en)
|
2015-08-31 |
2017-07-27 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
JP2019505498A
(ja)
|
2015-12-16 |
2019-02-28 |
ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ |
Nk細胞におけるサイトカイン誘導性sh2タンパク質の阻害
|
MA43650A
(fr)
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprenant un inhibiteur de btk
|
EP3405177A1
(de)
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica NV |
Formulierungen/zusammensetzungen mit einem btk-inhibitoren
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
AU2017246334C1
(en)
|
2016-04-04 |
2022-11-17 |
Sinopia Biosciences, Inc. |
Treating extrapyramidal syndrome using Trapidil
|
CA3025268A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
EP3957629B1
(de)
|
2016-07-18 |
2023-09-06 |
Arthrosi Therapeutics, Inc. |
Verfahren zur herstellung von deuteriertem hydroxy-benzbromaron und deren zwischenprodukten
|
MX2019002259A
(es)
|
2016-08-26 |
2019-09-18 |
Curtana Pharmaceuticals Inc |
Inhibicion de la actividad de la olig2.
|
UA124884C2
(uk)
|
2016-11-16 |
2021-12-08 |
Лундбек Ла Джолла Ресеарч Центер, Інк. |
Фармацевтичні склади
|
CA3043610A1
(en)
|
2016-11-16 |
2018-05-24 |
Abide Therapeutics, Inc. |
Crystalline forms of a magl inhibitor
|
WO2019046731A1
(en)
|
2017-09-01 |
2019-03-07 |
University Of Washington |
CRYSTALLINE FORMS OF COMPOUNDS FOR PREVENTING OR TREATING DEATH OF SENSORY CILIC CELLS
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
JP2022516057A
(ja)
|
2018-12-31 |
2022-02-24 |
バイオメア フュージョン,エルエルシー |
メニン-mll相互作用の不可逆的阻害剤
|
KR20220009373A
(ko)
|
2019-03-15 |
2022-01-24 |
유니사이시브 테라퓨틱스 인코포레이티드 |
니코란딜 유도체
|
JP2023523219A
(ja)
|
2020-04-21 |
2023-06-02 |
ハー・ルンドベック・アクチエゼルスカベット |
モノアシルグリセロールリパーゼ阻害剤の合成
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
WO2022150525A1
(en)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma in the treatment of alcohol use disorder
|
EP4337316A1
(de)
|
2021-05-11 |
2024-03-20 |
Awakn Ls Europe Holdings Limited |
Therapeutische aminoindanverbindungen und zusammensetzungen
|
CA3221280A1
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
TW202320796A
(zh)
|
2021-08-11 |
2023-06-01 |
美商拜歐米富士恩股份有限公司 |
用於糖尿病的menin-mll相互作用之共價抑制劑
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|